Last reviewed · How we verify
Penicillin G Potassium In Plastic Container (Benzylpenicillin)
Penicillin G Potassium In Plastic Container (generic name: Benzylpenicillin) is a Penicillin-class Antibacterial Small molecule drug developed by Pfizer. It is currently FDA-approved (first approved 1947) for Abdominal actinomycosis, Abscess of lung, Actinomycotic infection.
Penicillin G Potassium is a small molecule antibiotic used to treat various bacterial infections, including pneumonia, strep throat, and syphilis. It is not a first-line agent for pneumococcal meningitis and is typically administered through routes other than oral medication due to its limited bioavailability.
At a glance
| Generic name | Benzylpenicillin |
|---|---|
| Sponsor | Pfizer |
| Drug class | Penicillin-class Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1947 |
Approved indications
- Abdominal actinomycosis
- Abscess of lung
- Actinomycotic infection
- Acute otitis media
- Anthrax
- Anthrax septicemia
- Aspiration pneumonia
- Asymptomatic Congenital Syphilis
- Bacterial endocarditis
- Bejel
- Cervicofacial actinomycosis
- Clostridium Perfringens Empyema
- Congenital syphilis
- Cutaneous anthrax
- Diphtheria
- Disseminated Gonococcal Infection
- Erysipelas
- Erysipeloid
- Fusospirochetal pharyngitis
- Gangrenous pneumonia
Common side effects
Key clinical trials
- Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting (NA)
- Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Penicillin G Potassium In Plastic Container CI brief — competitive landscape report
- Penicillin G Potassium In Plastic Container updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Penicillin G Potassium In Plastic Container
What is Penicillin G Potassium In Plastic Container?
What is Penicillin G Potassium In Plastic Container used for?
Who makes Penicillin G Potassium In Plastic Container?
What is the generic name of Penicillin G Potassium In Plastic Container?
What drug class is Penicillin G Potassium In Plastic Container in?
When was Penicillin G Potassium In Plastic Container approved?
What development phase is Penicillin G Potassium In Plastic Container in?
Related
- Drug class: All Penicillin-class Antibacterial drugs
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Abdominal actinomycosis
- Indication: Drugs for Abscess of lung
- Indication: Drugs for Actinomycotic infection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing